At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 75 enrolled

Drug / intervention

insulin glargine +2 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00338104

NCT00338104Phase 4Completed

Compare CT.gov

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

Northwestern University·interventional·Posted Jun 20, 2006·Updated Apr 6, 2009

In Brief

A Phase 4 clinical trial evaluating insulin glargine for Hyperglycemia and Diabetes. Completed, enrolled 75 participants across 1 site.

Detailed Summary

The primary objective of this study is to determine the optimal dose of glargine insulin when converting from intravenous short-acting continuous insulin infusions in surgical and intensive care unit patients using a prospective, controlled, parallel group, randomized study design. Note: Lantus insulin is the proprietary name for glargine insulin.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHyperglycemia, Diabetes

CountriesUnited States

CollaboratorsSanofi

Timeline

Phase 4CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJul 2004

Primary CompletionMay 2005

First PostedJun 2006

TodayJul 2026

First PostedJun 20, 2006

Enrollment StartJul 1, 2004

Primary CompletionMay 1, 2005

TodayJul 2, 2026

Enrollment to primary: 10 monthsPosted 20.0 years ago

Interventions

insulin glarginedrug

Insulin glargine given at 40% of prior stable drip rate.

insulin glarginedrug

Insulin glargine given at 60% of prior stable drip rate.

insulin glarginedrug

Insulin glargine given at 80% of prior stable drip rate.